These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

176 related articles for article (PubMed ID: 36357378)

  • 1. SR9009 inhibits lethal prostate cancer subtype 1 by regulating the LXRα/FOXM1 pathway independently of REV-ERBs.
    Xu H; Zhang J; Zheng X; Tan P; Xiong X; Yi X; Yang Y; Wang Y; Liao D; Li H; Wei Q; Ai J; Yang L
    Cell Death Dis; 2022 Nov; 13(11):949. PubMed ID: 36357378
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The Putatively Specific Synthetic REV-ERB Agonist SR9009 Inhibits IgE- and IL-33-Mediated Mast Cell Activation Independently of the Circadian Clock.
    Ishimaru K; Nakajima S; Yu G; Nakamura Y; Nakao A
    Int J Mol Sci; 2019 Dec; 20(24):. PubMed ID: 31847374
    [TBL] [Abstract][Full Text] [Related]  

  • 3. SR9009 induces a REV-ERB dependent anti-small-cell lung cancer effect through inhibition of autophagy.
    Shen W; Zhang W; Ye W; Wang H; Zhang Q; Shen J; Hong Q; Li X; Wen G; Wei T; Zhang J
    Theranostics; 2020; 10(10):4466-4480. PubMed ID: 32292508
    [No Abstract]   [Full Text] [Related]  

  • 4. Pharmacological activation of REV-ERBs is lethal in cancer and oncogene-induced senescence.
    Sulli G; Rommel A; Wang X; Kolar MJ; Puca F; Saghatelian A; Plikus MV; Verma IM; Panda S
    Nature; 2018 Jan; 553(7688):351-355. PubMed ID: 29320480
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Stimulation of nuclear receptor REV-ERBs suppresses production of pronociceptive molecules in cultured spinal astrocytes and ameliorates mechanical hypersensitivity of inflammatory and neuropathic pain of mice.
    Morioka N; Kodama K; Tomori M; Yoshikawa K; Saeki M; Nakamura Y; Zhang FF; Hisaoka-Nakashima K; Nakata Y
    Brain Behav Immun; 2019 May; 78():116-130. PubMed ID: 30682503
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Pharmacological Targeting the REV-ERBs in Sleep/Wake Regulation.
    Amador A; Huitron-Resendiz S; Roberts AJ; Kamenecka TM; Solt LA; Burris TP
    PLoS One; 2016; 11(9):e0162452. PubMed ID: 27603791
    [TBL] [Abstract][Full Text] [Related]  

  • 7. REV-ERB Agonist SR9009 Regulates the Proliferation and Neurite Outgrowth/Suppression of Cultured Rat Adult Hippocampal Neural Stem/Progenitor Cells in a Concentration-Dependent Manner.
    Shimozaki K
    Cell Mol Neurobiol; 2022 Aug; 42(6):1765-1776. PubMed ID: 33599915
    [TBL] [Abstract][Full Text] [Related]  

  • 8. REV-ERB agonism suppresses osteoclastogenesis and prevents ovariectomy-induced bone loss partially via FABP4 upregulation.
    Song C; Tan P; Zhang Z; Wu W; Dong Y; Zhao L; Liu H; Guan H; Li F
    FASEB J; 2018 Jun; 32(6):3215-3228. PubMed ID: 29401617
    [TBL] [Abstract][Full Text] [Related]  

  • 9. SR9009 has REV-ERB-independent effects on cell proliferation and metabolism.
    Dierickx P; Emmett MJ; Jiang C; Uehara K; Liu M; Adlanmerini M; Lazar MA
    Proc Natl Acad Sci U S A; 2019 Jun; 116(25):12147-12152. PubMed ID: 31127047
    [TBL] [Abstract][Full Text] [Related]  

  • 10. REV-ERBs negatively regulate mineralization of the cementoblasts.
    Fu L; Wang M; Zhu G; Zhao Z; Sun H; Cao Z; Xia H
    Biochem Biophys Res Commun; 2022 Jan; 587():9-15. PubMed ID: 34861472
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Circadian Clock REV-ERBs Agonist SR9009 Induces Synergistic Antitumor Activity in Multiple Myeloma by Suppressing Glucose-Regulated Protein 78-Dependent Autophagy and Lipogenesis.
    Wang R; Liu SL; Guo QQ; Shi XH; Ma MM
    World J Oncol; 2023 Dec; 14(6):464-475. PubMed ID: 38022411
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Targeting Prostate Cancer Subtype 1 by Forkhead Box M1 Pathway Inhibition.
    Ketola K; Munuganti RSN; Davies A; Nip KM; Bishop JL; Zoubeidi A
    Clin Cancer Res; 2017 Nov; 23(22):6923-6933. PubMed ID: 28899970
    [No Abstract]   [Full Text] [Related]  

  • 13. Regulation of exercise ability and glycolipid metabolism by synthetic SR9009 analogues as new REV-ERB-α agonists.
    Li L; Yang C; Qiao X; Yang X; Zhang J; Cui M; Li Z; Tian A; Li X; Zou X; Li Y; He W; Chen Y; He X
    Bioorg Med Chem; 2024 Sep; 111():117845. PubMed ID: 39059249
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Pharmacological and Genetic Modulation of REV-ERB Activity and Expression Affects Orexigenic Gene Expression.
    Amador A; Wang Y; Banerjee S; Kameneka TM; Solt LA; Burris TP
    PLoS One; 2016; 11(3):e0151014. PubMed ID: 26963516
    [TBL] [Abstract][Full Text] [Related]  

  • 15. REV-ERB agonist suppresses IL-17 production in γδT cells and improves psoriatic dermatitis in a mouse model.
    Wang S; Kozai M; Mita H; Cai Z; Masum MA; Ichii O; Takada K; Inaba M
    Biomed Pharmacother; 2021 Dec; 144():112283. PubMed ID: 34628169
    [TBL] [Abstract][Full Text] [Related]  

  • 16. REV-ERBα agonist SR9009 suppresses IL-1β production in macrophages through BMAL1-dependent inhibition of inflammasome.
    Hong H; Cheung YM; Cao X; Wu Y; Li C; Tian XY
    Biochem Pharmacol; 2021 Oct; 192():114701. PubMed ID: 34324866
    [TBL] [Abstract][Full Text] [Related]  

  • 17. REV-ERBβ is required to maintain normal wakefulness and the wake-inducing effect of dual REV-ERB agonist SR9009.
    Amador A; Kamenecka TM; Solt LA; Burris TP
    Biochem Pharmacol; 2018 Apr; 150():1-8. PubMed ID: 29355503
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Suppression of atherosclerosis by synthetic REV-ERB agonist.
    Sitaula S; Billon C; Kamenecka TM; Solt LA; Burris TP
    Biochem Biophys Res Commun; 2015 May; 460(3):566-71. PubMed ID: 25800870
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Rev-erb agonist improves adverse cardiac remodeling and survival in myocardial infarction through an anti-inflammatory mechanism.
    Stujanna EN; Murakoshi N; Tajiri K; Xu D; Kimura T; Qin R; Feng D; Yonebayashi S; Ogura Y; Yamagami F; Sato A; Nogami A; Aonuma K
    PLoS One; 2017; 12(12):e0189330. PubMed ID: 29232411
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Pharmacological activation of the nuclear receptor REV-ERB reverses cognitive deficits and reduces amyloid-β burden in a mouse model of Alzheimer's disease.
    Roby DA; Ruiz F; Kermath BA; Voorhees JR; Niehoff M; Zhang J; Morley JE; Musiek ES; Farr SA; Burris TP
    PLoS One; 2019; 14(4):e0215004. PubMed ID: 30973894
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.